Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy for iron deficiency - Says it will change reporting currency to US dollars from pound sterling from 2023 results. Says the interim results for the first half of 2023 will include condensed and consolidated US dollar financial information for the period and full-year 2022.
Current stock price: 10.92 pence, up 1.6%
12-month change: down 14%
By Greg Rosenvinge, Alliance News reporter
Comments and questions to newsroom@alliancenews.com
Copyright 2023 Alliance News Ltd. All Rights Reserved.


(Alliance News) - The following is a round-up of earnings and trading updates by London-listed companies, issued on Friday and not separately reported...


(Alliance News) - Stock prices in London were lower at midday on Friday, as hopes of diplomatic progress in the Middle East, and a batch of domestic d...


(Sharecast News) - Shield Therapeutics reported first-quarter net revenue of $18m and positive EBIT on Friday, helped by a China milestone payment and...


Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy ...


Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy ...


Shield Therapeutics PLC - Gateshead Quays, England-based commercial stage pharmaceutical company focused on the commercialisation of its oral therapy ...


(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Thursday.


(Alliance News) - Shield Therapeutics PLC on Thursday said revenue in 2022 rose amid a jump in sales of its Accrufer iron tablets, also known as Ferac...


(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:


(Alliance News) - Shield Therapeutics PLC on Thursday said it has raised GBP2.6 million through an open offer.